Current cancer management strategies fail to adequately treat malignancies with chemotherapy, with multivariable dose restrictive factors such as systemic toxicity and multidrug resistance; hence limiting therapeutic benefits, quality of life, and complete long-term remission rates. The resistance of cancer cells to anticancer drugs is one of the major reasons for the failure of traditional cancer treatments.
Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy / Enrico Mini, Ida Landini, Antonello Di Paolo, Gloria Ravegnini, Simona Saponara, Maria Frosini, Andrea Lapucci, Stefania Nobili. - STAMPA. - (2022), pp. 199-240.
Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy
Enrico Mini;Ida Landini;Andrea Lapucci;
2022
Abstract
Current cancer management strategies fail to adequately treat malignancies with chemotherapy, with multivariable dose restrictive factors such as systemic toxicity and multidrug resistance; hence limiting therapeutic benefits, quality of life, and complete long-term remission rates. The resistance of cancer cells to anticancer drugs is one of the major reasons for the failure of traditional cancer treatments.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
